Together, our results suggest ARIH1 is the E3 ligase for PD-L1, which could lead to the development of therapeutic strategies to overcome immunotherapy resistance in cancers and enhance checkpoint blockade therapy efficacy. The gene discussed is ARIH1; the disease is cancer.